Ascendis Pharma A/S
ASNDHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Ascendis Pharma A/S (ASND) is listed under Biotechnology. With a market capitalization of $16.01B, it sits in large-cap territory. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Market Cap
$16.01B
Beta
—
P/E (TTM)
18.31
P/E (Fwd)
22.53
EPS (TTM)
$13.29
EPS (Fwd)
$10.80
ROE
118.8%
ROA
9.6%
Cash
$812.3M
Total Debt
$450.1M
Free CF
$12.8M
52W Change
20.5%
Annual Financials
Cash vs Debt
Where ASND stands vs its 150-day and 200-day moving averages
As of the October 14, 2026 close, ASND finished 7.22% below its 150-day moving average ($240.59) and 5.52% below its 200-day moving average ($236.26). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ASND overbought or oversold?
At the October 14, 2026 close, ASND's RSI(14) was 50.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Ascendis Pharma A/S holds $812.3M in cash against $450.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $12.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 118.8%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 9.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $51.2M (2022) to $720.1M (2025), reflecting a 1307% increase over the period.
Investors considering Ascendis Pharma A/S should weigh the typical risks associated with ASND's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Ascendis Pharma A/S's trajectory.